Drug Trial Radar · NCT07422675
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Jan 31, 2027
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Serina TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
Conditions
- PARKINSON DISEASE (Disorder)
- Advanced Parkinson's Disease
Interventions
SER-252 (PEOZ-apomorphine)Drug
SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product.
enFuseDevice
The enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Temporal Profile of Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose through Day 21 (7 days after the Day 14 end-of-participation visit).
- Incidence of Moderate or Severe TEAEs Related to Study InterventionTime frame: From first dose through Day 21 (7 days after the Day 14 end-of-participation visit).
- Incidence of Serious Adverse Events (SAEs), including suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From first dose through Day 44 (30 days after the Day 14 end-of-participation visit).
- Change from Baseline in Vital SignsTime frame: Baseline to Day 8 (with Day 14 follow-up vitals also collected)
- Area under the concentration-time curve (AUC0-24, AUC0-96, AUC0-∞)Time frame: Day 1 through Day 8 (0-168 hours post-dose)
- Change from Baseline in Corrected QT Interval (QTcF)Time frame: Baseline to Day 8 (with Day 14 safety follow-up ECGs).
- Time to Maximum Plasma Concentration (Tmax)Time frame: Day 1 through Day 8 (0-168 hours post-dose).
- Change from Baseline in Clinical Laboratory ParametersTime frame: Baseline to Day 8 (laboratories at safety follow-up only if needed to follow up abnormalities).
- Fluctuation Index (FI)Time frame: Day 1 through Day 8 (0-168 hours)
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)Time frame: Screening/Day -1 and Day 8.
- Trough Concentration (Ctrough)Time frame: Days 2-8 (24-168 hours post-dose).
- Coefficient of Variation (CV%) for ExposureTime frame: Day 1 through Day 8 (0-168 hours).
- Distributional Half-Life (h)Time frame: Day 1 through Day 8
- Maximum Plasma Concentration (Cmax)Time frame: Day 1 through Day 8 (0-168 hours post-dose)
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Rocky Mountain Clinical Research
Englewood, Colorado · Recruiting
Velocity Clinical Research
Hallandale, Florida · Recruiting
K2 Medical Research LLC
Maitland, Florida · Recruiting
Quest Research Institute
Farmington Hills, Michigan · Recruiting
Inland Northwest Research
Spokane, Washington · Recruiting
CMAX
Adelaide, South Australia, Australia · Recruiting
Monash
Melbourne, Victoria, Australia · Completed
Shaung Ho Hospital - Clinical Research Center
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.